Recent Posts
Connect with:
Saturday / July 20.
HomeminewsAlcon Expands Ophthalmic Pharmacy Footprint

Alcon Expands Ophthalmic Pharmacy Footprint

Alcon has completed its purchase of Aerie Pharmaceuticals, enhancing its ophthalmic pharmaceutical portfolio.

Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.

Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.

Alcon CEO David Endicott says Alcon has a “rich history in the ophthalmic pharmaceutical space… we are excited to add Aerie’s significant technical expertise to Alcon R&D, which enhances our efforts to build a compelling portfolio of ophthalmic pharmaceuticals”.

Alcon intends to fully integrate Aerie into its business. The company previously disclosed it used debt to fund the transaction for a total purchase consideration of approximately US$930 million.